Cerevance

Cerevance company information, Employees & Contact Information

Explore related pages

Related company profiles:

Cerevance

Company Details

Employees
53
Founded
-
Address
One Marina Park Drive, Suite 1410,united Kingdom
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Boston, MA
Looking for a particular Cerevance employee's phone or email?

Cerevance Questions

News

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 - Yahoo Finance

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025 Yahoo Finance

Cerevance to Present Phase 2 Data on Solengepras in - GlobeNewswire

Cerevance to Present Phase 2 Data on Solengepras in GlobeNewswire

Cerevance Reports Positive Phase 1 Clinical Trial Results for KCNK13 Inhibitor and Upcoming Presentations at AAIC 2025 - Nasdaq

Cerevance Reports Positive Phase 1 Clinical Trial Results for KCNK13 Inhibitor and Upcoming Presentations at AAIC 2025 Nasdaq

Cerevance fails phase 2 trial in early, untreated Parkinson's - Fierce Biotech

Cerevance fails phase 2 trial in early, untreated Parkinson's Fierce Biotech

Cerevance Presents Topline Results from Phase 2 ASCEND - GlobeNewswire

Cerevance Presents Topline Results from Phase 2 ASCEND GlobeNewswire

Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback - Clinical Trials Arena

Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback Clinical Trials Arena

Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists - ACS Publications

Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists ACS Publications

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial - The Lancet

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial The Lancet

NETSseq's Impact On Cerevance's Approach to Drug Discovery - Pharmaceutical Executive

NETSseq's Impact On Cerevance's Approach to Drug Discovery Pharmaceutical Executive

Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - Pharma Voice

Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders Pharma Voice

A revival in neuro therapeutics - Fierce Pharma

A revival in neuro therapeutics Fierce Pharma

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor - ACS Publications

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor ACS Publications

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy - Clinical Trials Arena

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy Clinical Trials Arena

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline - GlobeNewswire

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline GlobeNewswire

Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease - Yahoo Finance

Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease Yahoo Finance

AD/PD 2025: Cerevance’s Solengepras falls short of primary endpoint in ASCEND trial - Clinical Trials Arena

AD/PD 2025: Cerevance’s Solengepras falls short of primary endpoint in ASCEND trial Clinical Trials Arena

Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023 - Clinical Trials Arena

Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023 Clinical Trials Arena

Parkinson Disease Agent CVN424 Shows Positive Results in Phase 2 Trial - NeurologyLive

Parkinson Disease Agent CVN424 Shows Positive Results in Phase 2 Trial NeurologyLive

Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras - Pharmaceutical Executive

Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras Pharmaceutical Executive

Cerevance Appoints Ottavio Vitolo, M.D., as Chief Medical Officer - citybiz

Cerevance Appoints Ottavio Vitolo, M.D., as Chief Medical Officer citybiz

Mixed results for Cerevance’s solengepras - The Pharma Letter

Mixed results for Cerevance’s solengepras The Pharma Letter

Cerevance's solengepras falls short in Phase II Parkinson's trial - FirstWord Pharma

Cerevance's solengepras falls short in Phase II Parkinson's trial FirstWord Pharma

Biotech Startup Cerevance Strikes Alzheimer’s Research Deal With Merck - The Wall Street Journal

Biotech Startup Cerevance Strikes Alzheimer’s Research Deal With Merck The Wall Street Journal

Merck forges Alzheimer’s pact with Cerevance - drugdiscoverytrends.com

Merck forges Alzheimer’s pact with Cerevance drugdiscoverytrends.com

Takeda taps brain-focused Cerevance in quest for new GI targets - Fierce Biotech

Takeda taps brain-focused Cerevance in quest for new GI targets Fierce Biotech

Merck & Co. partners with Cerevance in hunt for new Alzheimer's targets - FirstWord Pharma

Merck & Co. partners with Cerevance in hunt for new Alzheimer's targets FirstWord Pharma

It’s time to find new targets for brain diseases instead of just pursuing old ones - statnews.com

It’s time to find new targets for brain diseases instead of just pursuing old ones statnews.com

Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs - MedCity News

Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs MedCity News

Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE - Fierce Biotech

Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE Fierce Biotech

Leadership transition at Cerevance - The Pharma Letter

Leadership transition at Cerevance The Pharma Letter

Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact - BioSpace

Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact BioSpace

Cerevance - The Pharma Letter

Cerevance The Pharma Letter

Gates, GV chip into $45M round for CNS biotech Cerevance - Fierce Biotech

Gates, GV chip into $45M round for CNS biotech Cerevance Fierce Biotech

A biotech startup gives Merck its next shot at treating Alzheimer’s - BioPharma Dive

A biotech startup gives Merck its next shot at treating Alzheimer’s BioPharma Dive

Biotech Startup Cerevance Extends Series B to $65 Million - The Wall Street Journal

Biotech Startup Cerevance Extends Series B to $65 Million The Wall Street Journal

Positive results for Cerevance’s Parkinson’s drug - PharmaTimes

Positive results for Cerevance’s Parkinson’s drug PharmaTimes

Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster - BioSpace

Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster BioSpace

Top Cerevance Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant